Inclusion Criteria:

          1. History of histologically confirmed colorectal adenocarcinoma metastatic to the liver
             with no clinically or radiographically confirmed extrahepatic disease (or)
             Histologically confirmed cholangiocarcinoma (Clinical or radiographic evidence of
             metastatic disease that has been resected is allowed, provided there is no recurrence
             in that area prior to protocol consent)

          2. Confirmation of diagnosis must be performed at VMMC

          3. Participant may have completely resected hepatic metastases without current evidence
             of other metastatic disease

          4. Lab values ≤14 days prior to registration:

             ANC ≥ 1.0(9)/L Platelet count ≥ 75 (9)/L Creatinine ≤1.8 mg/dL AST 0 to 2x reference
             value ALK PHOS 0 to < 1.2 x reference value Tot Bili 0 to < 1.2 x reference value

          5. Prior chemotherapy is acceptable if last dose of oxaliplatin or irinotecan is given ≥3
             weeks prior to planned first dosing on this protocol. 5-FU or 5-FU leucovorin may be
             given ≥2 weeks prior to planned first dosing on this protocol. [Note: no chemotherapy
             to be given after resection of liver lesions prior to treatment on this study]

          6. Any investigation agent is acceptable if administered ≥3 months before planned first
             dose on this protocol

          7. ECOG <=1

          8. Participants ≥18 years of age

        Exclusion Criteria:

          1. Prior radiation to the liver (prior radiation therapy to the pelvis is acceptable if
             competed at least 4 weeks prior to the planned first dose of treatment on protocol)

          2. Colorectal cancer that is BRAF mutant or defective in mismatch repair.

          3. Active infection, ascites, hepatic encephalopathy

          4. Female participants who are pregnant or lactating - or planning to become pregnant
             within 6 months after the end of the treatment (female participants of child-bearing
             potential must have negative pregnancy test ≤72 hours before treatment start)

          5. If in the opinion of the treating investigator a participant has any serious medical
             problems which may preclude receiving this type of treatment

          6. Participants with current evidence of hepatitis A, B, C (i.e., active hepatitis)

          7. Participants with history or known presence of primary CNS tumors, seizures not well-
             controlled with standard medical therapy, or history of stroke will also be excluded

          8. Serious or non-healing active wound, ulcer, or bone fracture

          9. History of other malignancy, except:

               1. Malignancy treated with curative intent and with no known active disease present
                  for ≥3 years prior to registration and felt to be at low risk for recurrence by
                  the treating physician

               2. Adequately treated non-melanomatous skin cancer or lentigo malignant without
                  evidence of disease

               3. Adequately treated cervical carcinoma in situ without evidence of disease